

Publications

1. Articles originaux

1. Bouaouiche S*, Ghione S*, Shaier R, Burgy O, Racoeur C, Derangère V, Bettaieb A, **Plenchette S**. Nitric oxide-releasing drug glyceryl trinitrate targets JAK2/STAT3 signaling migration and invasion of triple-negative breast cancer cells. (2021) *International Journal of Molecular Sciences* 22(16), 8449. (IF 5.923)
2. Bouaouiche S*, Magadou L*, Dondaine L, Reveneau S, Isambert N, Bettaieb A, Jeannin JF, Laurens V*, **Plenchette S***. Glyceryl trinitrate-induced cytotoxicity of docetaxel-resistant prostatic cancer cells is associated with differential regulation of clusterin. (2019) *International Journal of Oncology*. 54 :1446-1456. (IF 3.899)
3. Romagny S, Bouaouiche S, Lucchi G, Ducoroy P, Bertoldo J, Terenzi H, Bettaieb A, **Plenchette S**. S-nitrosylation of cIAP1 switches cancer cell fate from TNF α /TNF-R1-mediated cell survival to cell death. (2018). *Cancer Res. Apr 15;78(8):1948-1957*. (IF 8.378)
4. Cartier J, Berthelet J, Marivin A, Gemble S, Edmond V, **Plenchette S**, Lagrange B, Hammann A, Dupoux A, Delva L, Eymin B, Solary E, Dubrez L. cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate e2F1-mediated control of cyclin transcription. (2011) *J Biol Chem*. 29;286(30):26406-17. (IF 4.773)
5. Leon-Bollotte L, Subramaniam S, Cauvard O, **Plenchette-Colas S**, Paul C, Godard C, Martinez-Ruiz A, Legembre P, Jeannin JF, and Bettaieb A. S-nitrosylation of the death receptor Fas amplifies Fas ligand-mediated cancer cell apoptosis. (2011) *Gastroenterology* 140(7):2009-18. (IF 11.675)
6. Mahoney DJ, Cheung HH, Mrad RL, **Plenchette S**, Simard C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J, Korneluk RG. Both cIAP1 and cIAP2 regulate TNF α -mediated NF- κ B activation. (2008) *PNAS* 105(33): 11778-83. (IF 9.38)
7. Cheung HH*, **Plenchette S***, Kern CJ, Mahoney DJ, Korneluk RG. The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways. (2008) *Mol Biol Cell*. 19(7): 2729-40. * co-first author. (IF 5.792)
8. Arora V, Cheung HH, **Plenchette S**, Micali OC, Liston P, Korneluk RG. Degradation of survivin by the XIAP-XAF1 complex. (2007) *J Biol Chem*. 282(36): 26202-26209. (IF 5.943)
9. OC Micali, HH Cheung, **S Plenchette**, SL Hurley, P Liston, EC LaCasse, RG Korneluk. Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN- β . (2007) *BMC Cancer*. Mar 21;7:52. (IF 3.143)
10. Ponnelle T, Chapusot C, Martin L, Bouvier AM, **Plenchette S**, Faivre J, Solary E, Piard F. (2005) Cellular localisation of Survivin: impact on the prognosis in colorectal cancer. *Journal of Cancer Research and Clinical Oncology*. 131(8):504-510. (IF 2.883)
11. **Plenchette S**, Cathelin S, Rebe C, Launay S, Ladoire S, Sordet O, Ponnelle T, Debili N, Phan TH, Padua RA, Dubrez-Daloz L, Solary E. (2004) Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal mediated event. *Blood*. 104(7):2035-43. (IF 9.56)
12. Ponnelle T, Chapusot C, Martin L, Bonithon-Kopp C, **Plenchette S**, Rageot D, Faivre J, Solary E, Piard F. (2003) Subcellular expression of c-IAP1, c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. *Pathology Research and Practice*. 199(11):723-31. (IF 0.967)
13. Parcellier A, Gurbuxani S, Seigneurin-Berny D, Pance A, Chantôme A, Schmitt E, **Plenchette S**, Khochbin S, Solary E, Garrido C. (2003) HSP27 is an ubiquitin-binding protein involved in I- κ Ba proteasomal degradation. *Molecular and Cellular Biology*. 23(16): 5790-5802. (IF 9.395)
14. Sordet O, Rebe C, **Plenchette S**, Zermati Y, Hermine O, Vainchenker W, Garrido C, Solary E, Dubrez-Daloz L. (2002) Specific involvement of caspases in the differentiation of monocytes into macrophages. *Blood*. 100(13):4446-4453. (IF 3.836)

15. **Plenchette S.**, Moutet M., Benguella M., N'Gondara J.P., Guigner F., Coffe C., Corcos L., Bettaieb A., Solary E. (2001) Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. *Leukemia*. 15(10):1572-1581. (IF 4.501)
16. Sordet O., Rebe C., Leroy I., Bruey J.M., Garrido C., Miguet C., Lizard G., **Plenchette S.**, Corcos L., Solary E. (2001) Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. *Blood*. 97(12):3931-3940. (IF 3.584)

2. Revues

1. Mabrouk N, Ghione S, Laurens V, **Plenchette S**, Bettaieb A, Paul C. Senescence and cancer: role of nitric oxide (NO) in SASP. (2020) *Cancers*. 2;12(5):1145. (IF 6.126)
2. Ghione S, Mabrouk N, Paul C, Bettaieb A, **Plenchette S**. Protein kinase inhibitor-based cancer therapies: considering the potential of nitric oxide (NO) to improve cancer treatment. (2020) *Biochem Pharmacol*. 176:113855. (IF 4.96)
3. Bettaieb A, Paul C, **Plenchette S**, Shan J, Chouchane L, Ghiringhelli F. Precision medicine in breast cancer: reality or utopia? (2017) *J Transl Med*. 15(1):139. (IF 4.197)
4. Bouaouiche S, Dubrez L, Bettaieb A, **Plenchette S**. IAPs: mediators of oncogenesis and targets for anti-cancer therapy. *Critical Review in Oncogenesis*. (2016) *Critical Reviews in Oncogenesis*. 21(5-6):399-411. (IF 2.79)
5. **Plenchette S**, Romagny S, Laurens V, Bettaieb A. NO and cancer: itinerary of a double agent. (2016) *Médecine sciences*. Jun-Jul ;32(6-7) :625-33. (IF 0.493)
6. **Plenchette S**, Romagny S, Laurens V, Bettaieb A. S-nitrosylation in TNF superfamily signaling pathway: implication in cancer. (2015) *Redox. Biol*. 6:507-15. (IF 7.44)
7. Magadoux L, Isambert N, **Plenchette S**, Jeannin JF and Laurens V. (2014). Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer. *Int J Oncology*. 45(3):919-28. (IF 3.025)
8. Marivin A, Berthelet J, **Plenchette S**, and Dubrez, L. The Inhibitor of Apoptosis (IAPs) in Adaptive Response to Cellular Stress. (2012) *Cells*. 1, 711-737. (IF 4.366)
9. LaCasse EC, Mahoney DJ, Cheung HH, **Plenchette S**, Baird S, Korneluk RG. IAP-targeted therapies for cancer. (2008) *Oncogene* 27(48):6252-6275. (IF 7.55)
10. **Plenchette S**, Cheung H, Fong WG, LaCasse E, Korneluk RG. The role of XAF1 in cancer. *Current Opinion in Investigational Drugs* (2007) 8:469-476. (IF 3.227)
11. Bettaieb A, Dubrez-Daloz L, Launay S, **Plenchette S**, Rébé C, Séverine C, Solary E. (2003) Bcl-2 proteins: targets and tools for chemosensitisation of tumor cells. *Current Medical Chemistry -Anti-Cancer Agents*. 3(4): 307-318. (IF 2.556)
12. Solary E., **Plenchette S.**, Sordet O., Rebe C., Ducoroy P., Filomenko R., Bruey J.M., Droin N., Corcos L. (2001) Modulation of apoptotic pathways triggered by cytotoxic agents. *Thérapie*. 56(5):511-518. (IF 0.5)

3. Chapitres de livres

1. **Plenchette S**, Paul C, Bettaieb A. Nitric oxide platinum derivatives-based regimens for cancer treatment: from preclinical studies to clinical trials. (2017). Nitric oxide (donor/inducer) in chemosensitization, Volume 1. 1st Edition. Academic Press. ISBN: 9780128164716.
2. Bettaieb A, Paul C, **Plenchette S**. Exploration of Fas S-nitrosylation by the Biotin Switch Assay. (2017) *Methods in Molecular Biology*. 1557:199-206. Springer Protocols. Humana Press.
3. Bettaieb A, **Plenchette S**, Paul C, Laurens V, Romagny S and Jeannin JF. S-nitrosylation in cancer cell: to prevent or to cause? (2015). Nitric oxide and Cancer: Pathogenesis and Therapy. p97-109. Springer. ISBN 978-3-319-13611-0.
4. Leon L, Lamrani M, **Plenchette-Colas S**, Jeannin JF, Bettaieb A. (2010) Forum on immunopathological diseases and therapeutics. 1 (4), 297-305. Begell House.

5. **Plenchette S**, Filomenko R, Logette E, Solier S, Buron N, Cathelin S, Solary E. (2004) Analyzing markers of apoptosis in vitro. *Methods in Molecular Biology*. 281:313-31. Springer Protocols. Humana Press.
6. Solary E., Droin N., Sordet O., Rebe C., Filomenko F., Wotawa A., **Plenchette S.**, and Ducoroy P. (2002) Cell death pathways as targets for anticancer drugs. From book: *Anticancer drug development*. 55-76. Edited by Bruce C. Baguley, David J. Kerr. Academic Press. ISBN-10: 0120726513.

4. Actes de congrès publiés

1. **Plenchette S**. Role of S-nitrosylation in the extrinsic apoptotic signaling pathway in cancer. (2015) *Redox Biol*. 5:415.
2. Cheung H, Arora V, Korneluk R, **Plenchette S**, Liston P. The IAP proteins and the XAF1 antagonist as cancer targets. (2005) *Clinical cancer research* 11 (24): 9175S-9176S Part 2 Suppl. S, Dec 15 2005.